Kala Pharmaceuticals, Inc., a leading developer of innovative ophthalmic products based on the company’s proprietary Mucus Penetrating Particle (MPP) platform, today announced the initiation of two clinical trials with its nanotechnology-based loteprednol etabonate MPP (LE-MPP) program, KPI-121.
CEA-Leti and Akrivis Technologies, LLC announced their collaboration to develop an extremely adaptable, efficient and highly targeted drug delivery platform for chemotherapy and other treatments that require a high concentration of powerful drugs to be delivered precisely to targeted cells.
BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced that it has entered into a research agreement with Roche to discover novel nanomedicines using Accurins for the treatment of diseases in therapeutic areas outside of oncology.
Several prominent speakers from across the globe that are part of Nanotek-2014 include Claudio Nicolini, Nanoworld Institute, Italy; Haruo Sugi, Teikyo University School of Medicine, Japan; Jim Klostergaard, MD Anderson Cancer Center, The University of Texas, USA; Israel Felner, The Hebrew University, Israel; Jean-Paul (Moshe) Lellouche, Bar-Ilan University, Israel; John F. Donegan, Trinity College Dublin, Ireland; Ashok K. Vaseashta, International Clean Water Institute, USA,; Kimihisa Yamamoto, Tokyo Institute of Technology, Japan; Serhii Shafraniuk, Northwestern University, USA; Mark Kester, NanoSTAR Institute of the University of Virginia, USA; Bjarne Bogen, University of Oslo and Oslo University Hospital, Norway; and Moinuddin Sarker, Natural State Research, Inc., USA.
Researchers from Tel Aviv University and partner institutions develop device that spots lung cancer to stop it in its tracks
Although liposuction is one of the most common and well-established cosmetic surgery procedures in the U.S., it still has its drawbacks. But a new biomedical start-up says it may have found a novel way to improve the procedure using gold nanoparticles to literally melt fat, reports Chemical & Engineering News (C&EN), the weekly news magazine of the American Chemical Society.
AuraSense Therapeutics, a Chicago-based biopharmaceutical company commercializing spherical nucleic acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, has announced the close of its Series C financing that included an investment by Bill Gates.
Celator Pharmaceuticals, Inc., a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that the company's management team will present at the following conferences in June:
Avidity NanoMedicines, a biopharmaceutical company pioneering development of the Antibody-siRNA Complex (ARC™) as a new therapeutic class, announced today the issuance of two new U.S. patents. ARCs™ combine the potency and specificity of biologics with a nucleic acid-based payload, representing a breakthrough approach to the targeted delivery of nucleic acid-based medicines.
Research and Markets has announced the addition of the "Nanoparticle Drug Delivery Market & Clinical Pipeline Insight" report to their offering.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.